Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
Date:11/9/2011

NEW YORK, Nov. 9, 2011 /PRNewswire/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that two abstracts highlighting potential cost savings based on clinical observations from clinical trials of Zerenex™ (ferric citrate) have been accepted for poster presentation at the upcoming American Society of Nephrology (ASN) Kidney Week 2011 Annual Meeting and exposition taking place November 8-13 in Philadelphia.

Friday, November 11, 2011 – Poster #1566

Abstract # 23502, entitled "TSAT and Serum Ferritin Increases Observed in Ferric Citrate Clinical Trials May Lead to Dialysis Cost Savings" will be presented on Friday, November 11, 2011 at 10:00am ET during the "Dialysis: Anemia, Malnutrition, and Metabolism – II" Poster Session, and will be available for viewing from 10:00am-12:00pm ET.

Saturday, November 12, 2011 – Poster #2647

Abstract # 23692, entitled "Physician Reaction to Spontaneous Rises in Transferrin Saturation and Serum Ferritin Levels in End Stage Renal Disease Patients" will be presented on Saturday, November 12, 2011 at 10:00am ET during the "Dialysis: Epidemiology, Outcomes, and Clinical Trials: Non-Cardiovascular – III" Poster Session, and will be available for viewing from 10:00am-12:00pm ET.

The above abstracts are currently available online for viewing through the ASN website at: http://www.asn-online.org/education_and_meetings/kidneyweek/archives/KW11Abstracts.pdf

The Zerenex Phase 3 registration program, which is being conducted pursuant to a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA), is comprised of an already successfully-completed Phase 3 short-term study, and an ongoing Phase 3 long-term study.

Keryx holds a worldwide lice
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
2. Keryx Biopharmaceuticals Notified that Nasdaq Has Extended Minimum Bid Price Rule Compliance Period
3. Keryx Biopharmaceuticals to Present at the J.P. Morgan 27th Annual Healthcare Conference
4. Keryx Biopharmaceuticals Inc. Announces Receipt of Nasdaq Delisting Notification
5. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Fourth Quarter and Year-End 2008 Financial Results on Friday, March 13, 2009 at 8:30am EDT
6. Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2008 Financial Results
7. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
8. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
9. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on First Quarter 2009 Financial Results on Thursday, May 14, 2009 at 8:30am EDT
10. Keryx Biopharmaceuticals Announces Poster Presentations Highlighting Clinical Activity of KRX-0401 (Perifosine) at the Upcoming Annual Meeting of the American Society of Clinical Oncology
11. Keryx Biopharmaceuticals Announces Appointment of Ron Bentsur as Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2015)... April 28, 2015 The Pistoia Alliance, ... work together to lower barriers to innovation in R&D, ... project. , The Ontologies Mapping project has been ... practices for ontology management in life sciences R&D. The ... of standardized guidelines, tools and services to enable the ...
(Date:4/28/2015)... According to a 2013 report from ... medical treatment from burn injuries per year. Despite several ... formation of scars with subsequent contractures remains a major ... there is no adequate treatment. Contractures are a permanent ... can cause permanent deformity. , Synedgen has developed ...
(Date:4/28/2015)... 28, 2015 Reproductive endocrinologist Dr. Kaylen ... 7 couples battling infertility in this country, testified on behalf ... as the first state in the nation to consider creating ... to couples who desire to receive them. , Infertility affects ... that infertility is one of the few medical diseases that ...
(Date:4/27/2015)... HEIDELBERG , Alemania, April 27, 2015 ... patente para un nuevo receptor utilizando tecnología de descubrimiento ... no cubierta en el tratamiento de millones de pacientes ... anunciado hoy que ha recibido una patente en Europa ... el descubrimiento de Molecular Health de que EPHB4 es ...
Breaking Biology Technology:Pistoia Alliance Announces Start of Ontologies Mapping Project 2Synedgen Burn Treatment Results Presented at Premier Wound Conference 2Synedgen Burn Treatment Results Presented at Premier Wound Conference 3Texas Fertility Center Supports a Groundbreaking HB1145 that Facilitates Embryo Donation in Texas 2Texas Fertility Center Supports a Groundbreaking HB1145 that Facilitates Embryo Donation in Texas 3Molecular Health obtiene la patente para un nuevo receptor 2Molecular Health obtiene la patente para un nuevo receptor 3
... 6 , 3Q09 Corporate Highlights: ... to Astellas Pharma Europe Ltd. Made significant progress ... VP Sales; Senior Director, Marketing; and Director, Commercial Operations ... Committee chairman , Upcoming 2009 Milestones: ...
... Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced ... REOLYSIN(R) in patients with sarcomas metastatic to the lung ... Tissue Oncology Society Meeting held in Miami Beach, Florida, ... "A Phase II Study of Intravenous REOLYSIN (Wild-type Reovirus) ...
... ... place on February 22-24, 2010 in Philadelphia, has been announced. At this three day ... to share their experiences. , ... Minneapolis, MN (PRWEB) November 6, 2009 -- The agenda for Arrowhead’s ...
Cached Biology Technology:NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 2Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting 3Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 2Leaders in Biopharma and Molecular Diagnostics to Discuss Key Issues and Opportunities in Forming Partnerships at 2010 Personalized Medicine Partnerships Conference 3
(Date:4/14/2015)... OXFORD, Conn. , April 14, 2015 ... "Company"), a biometric authentication company focused on the growing ... has been nominated for the 2015 New York Design ... The Design100, New York City Design Awards are ... are based on over 2,500 ratings from the marketplace, ...
(Date:4/13/2015)... -- higi, a leading cloud-based consumer engagement platform that provides ... their communities around health and wellness, announced today the ... ... convenient vehicle to receive validated health information from consumers. ... API will allow higi,s trusted partners, on a user ...
(Date:4/9/2015)... Synaptics Inc. (NASDAQ: SYNA ), a leading ... will report financial results for the third quarter of ... close of market. The company will host a corresponding ... PT (5:00 p.m. ET), during which management may discuss ... live call, analysts and investors should dial 888-438-5524 (conference ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 2NXT-ID's Wocket Smart Wallet Nominated for 2015 New York Design Awards in 'Product Design- Technology' 3higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 2higi Launches Seamless Access to HIPAA-Compliant Health Outcomes and Activity Data 3Synaptics to Report Third Quarter Results on April 23 2
... decades, crop breeders have increasingly relied on the wild and ... resistance, drought tolerance, and other traits. But just like all ... at risk of decline and extinction due to habitat loss, ... two speakers will describe the latest efforts to identify and ...
... Ohio The discovery of genetic differences affecting up ... guesswork out of prescribing the correct dose of 25 ... The scientists found two genetic variants that alter ... or metabolizing, drugs ranging from the painkiller codeine to ...
... 10 per cent of the UK is left handed ... world. But why exactly someone is left or right handed ... Nottingham,s Professor John Armour and Dr Angus Davison, in collaboration ... genetic determinant, in influencing handedness. The researchers conducted ...
Cached Biology News:Protecting the weedy and wild kin of globally important crops 2New genetic discovery could reduce the guesswork in drug dosing 2New genetic discovery could reduce the guesswork in drug dosing 3New genetic discovery could reduce the guesswork in drug dosing 4What makes us left or right handed? New study rules out strong genetic factors 2